• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo

NeuroAge Therapeutics Launches Younger 2027


  • Please log in to reply
No replies to this topic

#1 Steve H

  • Guest
  • 127 posts
  • 492
  • Location:UK
  • NO

Posted Today, 03:50 PM


NeuroAge Therapeutics announced Younger 2027, a six-month biological aging contest in which competitors are measured on a clinical-grade aging panel and retested six months later. Baseline testing kits begin shipping September 1, 2026, with at-home baseline testing open through February 1, 2027. A live kickoff conference open to competitors and the broader longevity community takes place January 11-12, 2027 at the Gateway Pavilion at Fort Mason in San Francisco. The contest concludes with a finale in November 2027.

Participants complete a clinical-grade baseline across brain, body, and face, run a six-month intervention window, and then are retested on the same panel.

The contest is hosted by NeuroAge Therapeutics in collaboration with TruDiagnostic, Harvard FaceAge, and Vero Bioscience, with science contributed by researchers from MIT, Harvard, Yale, and Stanford.

The Panel

Every Competitor receives baseline and retest measurements across brain, body, and face. The standard panel includes TruDiagnostic’s TruAge platform (epigenetic clocks, SymphonyAge across 11 organ systems, and TruHealth clinical biomarkers), NeuroAge’s NeuroGames cognitive assessment, Harvard’s FaceAge model, and functional measurements (VO2 max, grip strength, sit-to-stand). Results from each partner are combined into a single composite score that tracks change between baseline and retest.

Ultra Competitors receive an extended panel that adds two brain MRIs, additional pre-release biological clocks including proteomic and methylation aging clocks, two sets of 100+ clinical biomarker panels, and two DEXA body composition scans. Several of these clocks are pre-release, giving Ultra participants early access ahead of public availability.

Kickoff at Fort Mason

The Fort Mason event is a two-day longevity conference open to Younger 2027 competitors and the wider longevity community, featuring keynote talks, a curated longevity expo, and hands-on workshops. Confirmed speakers include Dr. Christin Glorioso (NeuroAge Therapeutics), Ryan Smith (TruDiagnostic), Dr. Ray Mak (FaceAge / Harvard Medical School), Dr. Raghav Sehgal (Yale), Dr. Ronjon Nag (Stanford Medicine / R42 Group), Dr. Steve Horvath (UCLA), Dr. Amy Killen (Humanaut Health), Paul Coletta (Vero Bioscience), and Dr. Momo Vuyisich (Viome). Participating clinic teams include California Center for Functional Medicine, VitOS, Humanaut Health, and Prime Health Associates.

Prizes and Awards

Younger 2027 award categories include:

  • The Younger Award (most years of biological age turned back)
  • The Forever Young Award (youngest biological age relative to chronological age)
  • The Ultra Younger Award (most years turned back on the Ultra panel)
  • The Ultra Forever Young Award (youngest biological age on the Ultra panel)
  • Organ-system category winners

Sponsoring partners contribute a $50,000 equivalent prize pool in cash, products, and services.

Registration

Registration is open at neuroagetx.com/events/younger. Early-bird pricing closes September 1, 2026.

About NeuroAge Therapeutics

NeuroAge Therapeutics combines cognitive testing, AI, and advanced diagnostics to help people measure and track brain health. Its multi-modal platform combines MRI, genetics, blood biomarkers, and cognitive testing into a single NeuroAge score tracked over time. NeuroAge was founded by Dr. Christin Glorioso, MD, PhD, a scientist trained at MIT and Harvard and the author of 30+ peer-reviewed publications. The company convenes Younger 2027. Learn more at neuroagetx.com.

Media Contact

Marah Doria

NeuroAge Therapeutics

Email: marah@neuroagetx.com

Web: neuroagetx.com/events/younger

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future.

View the article at lifespan.io




3 user(s) are reading this topic

0 members, 3 guests, 0 anonymous users